ArticleClinicoEconomics and outcomes research : CEOR2018

Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes.

Enrico Torre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.